CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Cefotaxime Sodium

头孢噻肟钠 杂质对照品Cefotaxime Sodium Impurities

EP23 个杂质条目23 impurity entries

本页汇总 头孢噻肟钠 的 23 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 23 impurity reference standards of Cefotaxime Sodium with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 头孢噻肟钠(Cefotaxime Sodium)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesGreen Chemometric Determination of Cefotaxime Sodium in the Presence of Its Degradation Impurities Using Different Multivariate Data Processing Tools; GAPI and AGREE Greenness Evaluation
    Molecules (Basel, Switzerland) · 2023 · Sharaf YA et al.  ·  PMID 36903432  ·  DOI
  2. 杂质研究Impurity studiesStudy of the polymerized impurities in cefotaxime sodium and cefepime by applying various chromatographic modes coupled with ion trap/time-of-flight mass spectrometry
    Talanta · 2022 · Ren X et al.  ·  PMID 34808572  ·  DOI
  3. 杂质研究Impurity studiesMethod Improving for Isolation and Characterization of Allergy-Inducing Polymer Impurities in Cefotaxime Sodium Medicines Available From Pharmaceutical Industry
    Frontiers in chemistry · 2022 · Fu Y et al.  ·  PMID 35295978  ·  DOI
  4. 分析方法Analytical MethodsA fluorometric chemosensor for the sequential determination of Fe(iii) and cefotaxime sodium in water samples, serum and commercial formulations: a computational and an experimental approach
    RSC advances · 2026 · Ullah I et al.  ·  PMID 41971025  ·  DOI
  5. 分析方法Analytical MethodsExploiting of Green Synthesized Metal Oxide Nanoparticles for Spectrophotometric Determination of Levofloxacin, Cephalexin, and Cefotaxime Sodium in Commercial Products
    Nanomaterials (Basel, Switzerland) · 2021 · Alarfaj NA et al.  ·  PMID 33923143  ·  DOI

头孢噻肟钠 —— 原料药与杂质对照品Cefotaxime Sodium — drug substance & impurities

共 23 个条目(含原料药本体)23 items incl. the drug substance
Cefotaxime Sodium structure
EP原料药 APIAPI
头孢噻肟钠Cefotaxime Sodium
Cefotaxime Sodium
CAS No.64485-93-4
Chemical FormulaC16H16N5O7S2-·Na+
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 3 (Cefotaxime Sodium EP Impurity C) structure
EPC
头孢噻肟钠杂质3 (头孢噻肟钠EP杂质C)Cefotaxime Sodium Impurity 3 (Cefotaxime Sodium EP Impurity C)
Cefotaxime Sodium Impurity 3 (Cefotaxime Sodium EP Impurity C)
CAS No.66403-32-5
Chemical FormulaC17H17N5O8S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 4 (Cefotaxime Sodium EP Impurity D) structure
EPD
头孢噻肟钠杂质4 (头孢噻肟钠EP杂质D)Cefotaxime Sodium Impurity 4 (Cefotaxime Sodium EP Impurity D)
Cefotaxime Sodium Impurity 4 (Cefotaxime Sodium EP Impurity D)
CAS No.63527-53-7
Chemical FormulaC16H17N5O7S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 6 (Cefotaxime Sodium EP Impurity F) structure
EPF
头孢噻肟钠杂质6 (头孢噻肟钠EP杂质F)Cefotaxime Sodium Impurity 6 (Cefotaxime Sodium EP Impurity F)
Cefotaxime Sodium Impurity 6 (Cefotaxime Sodium EP Impurity F)
CAS No.175032-97-0
Chemical FormulaC30H30N10O12S4
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 7 (Cefotaxime Sodium EP Impurity G) structure
EPG
头孢噻肟钠杂质7 (头孢噻肟钠EP杂质G)Cefotaxime Sodium Impurity 7 (Cefotaxime Sodium EP Impurity G)
Cefotaxime Sodium Impurity 7 (Cefotaxime Sodium EP Impurity G)
CAS No.2489535-06-8
Chemical FormulaC22H22N8O9S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime structure
—
头孢噻肟Cefotaxime
Cefotaxime
CAS No.63527-52-6
Chemical FormulaC16H17N5O7S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 11 structure
11
头孢噻肟钠杂质11Cefotaxime Sodium Impurity 11
Cefotaxime Sodium Impurity 11
CAS No.60846-14-2
Chemical FormulaC7H11NO4
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 14 structure
14
头孢噻肟钠杂质14Cefotaxime Sodium Impurity 14
Cefotaxime Sodium Impurity 14
CAS No.64485-88-7
Chemical FormulaC8H11N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 15 structure
15
头孢噻肟钠杂质15Cefotaxime Sodium Impurity 15
Cefotaxime Sodium Impurity 15
CAS No.76-83-5
Chemical FormulaC19H15Cl
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 23 structure
23
头孢噻肟钠杂质23Cefotaxime Sodium Impurity 23
Cefotaxime Sodium Impurity 23
CAS No.83305-12-8
Chemical FormulaC15H16BrN3O8S
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 26 structure
26
头孢噻肟钠杂质26Cefotaxime Sodium Impurity 26
Cefotaxime Sodium Impurity 26
CAS No.97466-27-8
Chemical FormulaC16H17N5O8S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 28 structure
28
头孢噻肟钠杂质28Cefotaxime Sodium Impurity 28
Cefotaxime Sodium Impurity 28
CAS No.75679-12-8
Chemical FormulaC14H15N5O6S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 29 structure
29
头孢噻肟钠杂质29Cefotaxime Sodium Impurity 29
Cefotaxime Sodium Impurity 29
CAS No.123238-79-9
Chemical FormulaC14H13N5O5S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 46 structure
46
头孢噻肟钠杂质46Cefotaxime Sodium Impurity 46
Cefotaxime Sodium Impurity 46
CAS No.94088-75-2
Chemical FormulaC13H10N4O2S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 49 structure
49
头孢噻肟钠杂质49Cefotaxime Sodium Impurity 49
Cefotaxime Sodium Impurity 49
CAS No.65243-09-6
Chemical FormulaC7H9N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 56 structure
56
头孢噻肟钠杂质56Cefotaxime Sodium Impurity 56
Cefotaxime Sodium Impurity 56
CAS No.147002-30-0
Chemical FormulaC26H24N6O11S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 57 structure
57
头孢噻肟钠杂质57Cefotaxime Sodium Impurity 57
Cefotaxime Sodium Impurity 57
CAS No.124667-21-6
Chemical FormulaC23H24N6O5S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 58 structure
58
头孢噻肟钠杂质58Cefotaxime Sodium Impurity 58
Cefotaxime Sodium Impurity 58
CAS No.84957-30-2
Chemical FormulaC23H24N6O5S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 60 structure
60
头孢噻肟钠杂质60Cefotaxime Sodium Impurity 60
Cefotaxime Sodium Impurity 60
CAS No.57254-16-7
Chemical FormulaC15H13N3O3S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 64 structure
64
头孢噻肟钠杂质64Cefotaxime Sodium Impurity 64
Cefotaxime Sodium Impurity 64
CAS No.66340-88-3
Chemical FormulaC7H10ClNO4
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 65 structure
65
头孢噻肟钠杂质65Cefotaxime Sodium Impurity 65
Cefotaxime Sodium Impurity 65
CAS No.64485-87-6
Chemical FormulaC7H10ClNO4
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 80 structure
80
头孢噻肟钠杂质80Cefotaxime Sodium Impurity 80
Cefotaxime Sodium Impurity 80
CAS No.75679-11-7
Chemical FormulaC14H15N5O6S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefotaxime Sodium Impurity 88 structure
88
头孢噻肟钠杂质88Cefotaxime Sodium Impurity 88
Cefotaxime Sodium Impurity 88
CAS No.64513-00-4
Chemical FormulaC7H9N3O3S
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

头孢噻肟钠 —— 研究文献与合成路线Cefotaxime Sodium — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 头孢噻肟钠 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Cefotaxime Sodium. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Green Chemometric Determination of Cefotaxime Sodium in the Presence of Its Degradation Impurities Using Different Multivariate Data Processing Tools; GAPI and AGREE Greenness Evaluation
    Sharaf YA, Ibrahim AE, El Deeb S, et al. · Molecules (Basel, Switzerland) · 2023 · 被引 7cited 7
  2. Relationship between the color stability and impurity profile of cefotaxime sodium
    Sun H, Cui X, Liu B, et al. · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2017 · 被引 1cited 1
  3. Study of the polymerized impurities in cefotaxime sodium and cefepime by applying various chromatographic modes coupled with ion trap/time-of-flight mass spectrometry
    Ren X, Zhu B, Gao J, et al. · Talanta · 2022 · 被引 7cited 7
  4. Effect of Moisture Content of Chitin-Calcium Silicate on Rate of Degradation of Cefotaxime Sodium
    Al-Nimry SS, Alkhamis KA · AAPS PharmSciTech · 2018 · 被引 4cited 4
  5. Method Improving for Isolation and Characterization of Allergy-Inducing Polymer Impurities in Cefotaxime Sodium Medicines Available From Pharmaceutical Industry
    Fu Y, Li J, Feng F, et al. · Frontiers in chemistry · 2022 · 被引 2cited 2

合成与制备工艺专利Synthesis & process patents

  1. Process for preparing cefotaxime sodium
    ZHAO YUSHAN, WANG LONGKE, KANG HENGJUN · 公开号 CN1634932CN1634932 · 2005
  2. PROCESS FOR THE PREPARATION OF CEFOTAXIME SODIUM
    DAS GAUTAM KUMAR, DESHPANDE PRAMOD NARAYAN, SRINIVASAN SHANMUGAM · 公开号 WO2004063203WO2004063203 · 2004
  3. PROCESS FOR THE PREPARATION OF CEFOTAXIME SODIUM
    DESHPANDE PRAMOD NARAYAN, SRINIVASAN SHANMUGAM, DAS GAUTAM KUMAR · 公开号 AU2003288635AU2003288635 · 2004
  4. IMPROVED PROCESS FOR THE PRODUCTION OF CEFOTAXIME SODIUM
    JAWEED MUKARRAM SIDDIQUI MOHAMMED, KHAN RASHID ABDUL REHMAN, YADAV RAM PRASAD, KHAN MOHAMMED YOUNUS · 公开号 WO2005076694WO2005076694 · 2005
  5. IMPROVED PROCESS FOR THE PRODUCTION OF CEFOTAXIME SODIUM
    JAWEED MUKARRAM SIDDIQUI, KHAN RASHID ABDUL, YADAV RAM, KHAN MOHAMMED · 公开号 EP1704153EP1704153 · 2006

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

头孢噻肟钠 杂质谱研究要点Cefotaxime Sodium — impurity profiling notes

下面这些是拿到 头孢噻肟钠 的 23 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 23 impurity entries for Cefotaxime Sodium, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances